Latest News - Lindis Initiates Clinical EU Certification Study REMOVE with CATUVAB®
A Targeted Approach
Blood Transfusions (BT) are necessary when a patient loses more than 0.5 liters of blood.and the haematocrit becomes low in a surgical procedure. Intraoperative Blood Salvage (IBS) is a technique frequently used during surgeries that have
A Targeted Approach
Blood Transfusions (BT) are necessary when a patient loses more than 0.5 liters of blood.and the haematocrit becomes low in a surgical procedure. Intraoperative Blood Salvage (IBS) is a technique frequently used during surgeries that have
Location: Germany, Brandenburg, Hennigsdorf
Total raised: $5.56M
Investors 2
| Date | Name | Website |
| - | BFB Brande... | brandenbur... |
| - | High-Tech ... | htgf.de |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.12.2019 | - | $5.56M | - |
Mentions in press and media 9
| Date | Title | Description |
| 13.12.2024 | Lindis Blood Care Raises Financing | Lindis Blood Care, a Hennigsdorf, Germany-based medical device company, raised an undisclosed amount in funding. The round was eldby Brandenburg Kapital. High-Tech Gründerfonds, existing and new private investors as well as the founders, Dr... |
| 10.01.2024 | Brandenburg Kapital - News about Lindis Blood Care GmbH | Hennigsdorf – January 2024. The Lindis Blood Care GmbH announced in December 2023 that the last patient in the clinical study REMOVE has also been treated successfully with CATUVAB®. The medical technology company aims to set a new standard... |
| 10.02.2022 | Lindis Blood Care successfully closes follow-on financing round | February 9, 2022 |
| 09.02.2022 | Lindis Blood Care successfully closes follow-on financing round | Hennigsdorf, Germany – 9th February, 2022. |
| 09.02.2022 | Lindis Blood Care successfully closes follow-on financing round | DGAP-News: Lindis Blood Care GmbH / Key word(s): Financing Lindis Blood Care successfully closes follow-on financing round 09.02.2022 / 10:00 The issuer is solely responsible for the content of this announcement. Lindis Blood Care successfu... |
| 10.11.2021 | Lindis Blood Care Announces Publication of Clinical Pilot Study Results Successfully Highlighting the Potential of CATUVAB(R) in the Removal of Tumor Cells from Surgical Blood in Peer-Reviewed Journal | DGAP-News: Lindis Blood Care GmbH / Key word(s): Study results Lindis Blood Care Announces Publication of Clinical Pilot Study Results Successfully Highlighting the Potential of CATUVAB(R) in the Removal of Tumor Cells from Surgical Blood i... |
| 13.12.2019 | Lindis Bloodcare Raises Over €5M in Total Funding | Lindis Bloodcare, a Hennigsdorf, Germany-based company developing a medical device to be used in oncology for the operation of tumours, raised over €5m in funding. Backers included: – High-Tech Gründerfonds (HTGF), – Brandenburg Kapital, – ... |
| - | Over 5 Million Euros For Lindis Blood Care: Development Of A New Product For The Removal Of Tumor Cells From Surgical Blood | |
| - | Brandenburg Kapital - News about Lindis Blood Care GmbH | Henningsdorf/Berlin - Dec. 2021. Lindis Blood Care, a portfolio company of Brandenburg Kapital that aims to revolutionize blood management during cancer surgeries with its medical device CATUVAB® for the removal of tumor cells from surgical... |